VisionCare Anticipates Big Boost From Expanded Telescope Implant Indication
This article was originally published in The Gray Sheet
FDA approved VisionCare Ophthalmic Technologies’ Implantable Miniature Telescope to treat macular degeneration in 65- to 74-year-old patients, expanding on the original 75-and-older indication and growing the potential market by about a third.
You may also be interested in...
CryoLife Executive Chairman retires. VisionCare Ophthalmic Technologies and Nihon Kohden, appoint new CEOs; Nephros appoints new leadership.
On many fronts, 2011 was an event-filled year for the retinal disease market, beginning with the publication of the CATT trial comparing off-label intravitreal Avastin versus Lucentis for the treatment of AMD, and ending with several important milestones for device manufacturers operating in this space. But while the retinal device field is making progress in many areas, companies continue to struggle to meet shifting FDA approval requirements.
CV Defense, the second launch in the firm’s new immune-support line (without cannabidiol), is built around palmitoylethanolamide and other nutrients and botanicals to “optimize immune response.” CV Sciences touts the immunity range as complementary to its PlusCBD brand, which is in the process of rolling out dozens of new products in updated packaging.